Third Point currently holds a 5.8% stake in the business, which specializes in the complex logistics of transporting human organs for transplant. In its filing, the investor argued that while the underlying operations remain robust, the company lacks the necessary scale to justify its heavy overhead. Furthermore, Third Point contends that existing management incentive structures fail to prioritize shareholder value, necessitating a shift in corporate strategy.

Following the disclosure, the market reacted with cautious optimism, pushing Strata shares up 3.9% to $4.51 in after-hours trading. The transition to a 13D filing marks a clear pivot for the investor, indicating a move to aggressively influence board decisions and organizational oversight moving forward.